Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

Makoto Kubo, Noriko Kanaya, Karineh Petrossian, Jingjing Ye, Charles Warden, Zheng Liu, Reiki Nishimura, Tomofumi Osako, Masayuki Okido, Kazuo Shimada, Masato Takahashi, Peiguo Chu, Yate Ching Yuan, Shiuan Chen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Aromatase inhibitors (AIs) are important drugs for treating postmenopausal patients with hormone receptor-positive breast cancer. However, acquired resistance to AI therapies is a significant problem. Our study has revealed that the histone deacetylase inhibitor LBH589 treatment abrogated growth of AI-resistant cells in vitro and in vivo, causing cell cycle G2/M arrest and induced apoptosis. LBH589 treatment also reduced the level of NF-κB1 which is overexpressed when AI resistance develops. Analyzing paired tumor specimens from 12 patients, we found that NF-κB1 expression was increased in recurrent AI-resistant tumors as compared to the paired primary tumors before AI treatment. This finding was consistent with up-regulated NF-κB1 expression seen in a collection of well-established AI-resistant cell lines. Furthermore, knockdown of NF-κB1 expression significantly suppressed the proliferation of AI-resistant cells. Treatment of AI-resistant cell lines with LBH589 suppressed NF-κB1 mRNA and protein expression. In addition, LBH589 treatment abrogated growth of AI-resistant tumors in mice, and was associated with significantly decreased levels of NF-κB1 in tumors. In all, our findings strongly support further investigation of LBH589 as a novel therapeutic strategy for patients with AI-resistant breast cancer, in part by suppressing the NF-κB1 pathway.

Original languageEnglish
Pages (from-to)93-107
Number of pages15
JournalBreast Cancer Research and Treatment
Volume137
Issue number1
DOIs
Publication statusPublished - Jan 2013

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)'. Together they form a unique fingerprint.

  • Cite this

    Kubo, M., Kanaya, N., Petrossian, K., Ye, J., Warden, C., Liu, Z., Nishimura, R., Osako, T., Okido, M., Shimada, K., Takahashi, M., Chu, P., Yuan, Y. C., & Chen, S. (2013). Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Research and Treatment, 137(1), 93-107. https://doi.org/10.1007/s10549-012-2332-x